Research progress on bile acid metabolism and its receptors regulating intestinal immunity in ulcerative colitis and traditional Chinese herbal medicine intervention
|更新时间:2023-08-28
|
Research progress on bile acid metabolism and its receptors regulating intestinal immunity in ulcerative colitis and traditional Chinese herbal medicine intervention
Shanghai Journal of Traditional Chinese MedicineVol. 57, Issue 9, Pages: 96-100(2023)
GAN Dan,YANG Haojie,HUANG Mian,et al.Research progress on bile acid metabolism and its receptors regulating intestinal immunity in ulcerative colitis and traditional Chinese herbal medicine intervention[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(9):96-100.
GAN Dan,YANG Haojie,HUANG Mian,et al.Research progress on bile acid metabolism and its receptors regulating intestinal immunity in ulcerative colitis and traditional Chinese herbal medicine intervention[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(9):96-100. DOI: 10.16305/j.1007-1334.2023.2211019.
Research progress on bile acid metabolism and its receptors regulating intestinal immunity in ulcerative colitis and traditional Chinese herbal medicine intervention
Ulcerative colitis (UC) is a chronic immune-mediated intestinal inflammatory disease caused by complex interactions among host genetic risk factors, environmental factors and gut microbiota imbalance, and can increase the risk of colorectal cancer. Specific bacterial metabolites, bile acids, can act as signal transduction molecules that affect the susceptibility of the host to intestinal inflammation. Dysregulated bile acid signaling may contribute to the dysregulation of the immune response in UC patients. In recent years, there has been considerable interest in the study of traditional Chinese herbal medicines (single herbs or extracts, herbal pairs and herbal formulas) interfering with bile acid metabolism and its receptors. We review the advances in the studies of bile acid metabolism and its receptors regulating intestinal immunity in UC patients and the intervention of traditional Chinese herbal medicines on bile acid metabolism and its receptors in order to provide ideas for the clinical treatment of ulcerative colitis.
关键词
溃疡性结肠炎胆汁酸代谢产物肠道菌群肠道免疫中药
Keywords
ulcerative colitisbile acidmetabolitesgut microbiotaintestinal immunitytraditional Chinese herbal medicine
references
BELOQUI A, MEMVANGA P, COCO R, et al. A comparative study of curcumin-loaded lipid-based nano carriers in the treatment of inflammatory bowel disease[J]. Colloids Surf B Biointerfaces, 2016, 143: 327-335.
CAZARIN C B, DA SILVA J K, COLOMEU T C, et al. Passiflora edulis peel intake and ulcerative colitis: approaches for prevention and treatment[J]. Exp Biol Med (Maywood), 2014, 239(5): 542-551.
XAVIER R J, PODOLSKY D K. Unravelling the pathogenesis of inflammatory bowel disease[J]. Nature, 2007, 448(7152): 427434.
POSTLER T S, GHOSH S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system[J]. Cell Metab, 2017, 26(1): 110-130.
KUIPERS F, DE BOER J F, STAELS B. Microbiome modulation of the host adaptive immunity through bile acid modification[J]. Cell Metab, 2020, 31(3): 445-447.
SINHA S R, HAILESELASSIE Y, NGUYEN L P, et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation[J]. Cell Host Microbe, 2020, 27(4): 659-670.
SONG X Y, SUN X M, OH S F, et al. Microbial bile acid metabolites modulate gut RORγ (+) regulatory T cell homeostasis[J]. Nature, 2020, 577(7790): 410-415.
DUBOC H, RAJCA S, RAINTEAU D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases[J]. Gut, 2013, 62(4): 531-539.
CHIANG J Y. Bile acid metabolism and signaling[J]. Compr Physiol, 2013, 3(3): 1191-1212.
FIORUCCI S, BALDONI M, RICCI P, et al. Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders[J]. Curr Opin Pharmacol, 2020, 53: 45-54.
FIORUCCI S, DISTRUTTI E, CARINO A, et al. Bile acids and their receptors in metabolic disorders[J]. Prog Lipid Res, 2021, 82: 101094.
LAVELLE A, SOKOL H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(4): 223-237.
MICHAUDEL C, SOKOL H. The Gut microbiota at the service of immunometabolism[J]. Cell Metab, 2020, 32(4): 514-523.
THOMAS J P, MODOS D, RUSHBROOK S M, et al. The emerging role of bile acids in the pathogenesis of inflammatory bowel disease[J]. Front Immunol, 2022, 13: 829525.
DING L, YANG L, WANG Z T, et al. Bile acid nuclear receptor FXR and digestive system diseases[J]. Acta Pharm Sinica B, 2015, 5(2) : 135-144.
CUI J Y, ALEKSUNES L M, TANAKA Y, et al. Bile acids via FXR initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 302(9) : 979-996.
FEROLLA S M, ARMILIATO G N, COUTO C A, et al. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease[J]. Nutrients, 2014, 6(12): 5583-5599.
GADALETA E, LEMOINE N R, CHELALA C. Online resources of cancer data: barriers, benefits and lessons[J]. Brief Bioinform, 2011, 12(1): 52-63.
WINSTON J A, THERIOT C M. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract[J]. Anaerobe, 2016, 41: 44-50.
COPPLE B L, LI T. Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules[J]. Pharmacol Res, 2016, 104: 9-21.
STAUDINGER J L, GOODWIN B, JONES S A, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity[J]. Proc Natl Acad Sci USA, 2001,98(6): 3369-3374.
MOORE L B, MAGLICH J M, MCKEE D D, et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors[J]. Mol Endocrinol, 2002, 16(5): 977-986.
SHAH Y M, MA X, MORIMURA K, et al. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression[J]. Am J Physiol Gastrointest Liver Physiol, 2007, 292(4): G1114-G1122.
MENCARELLI A, RENGA B, PALLADINO G, A. et al. Inhibition of NF-κB by a PXR dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells[J]. Eur J Pharmacol, 2011, 668(1-2): 317-324.
WILSON A, ALMOUSA A, TEFT W A, et al. Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn's disease[J]. Sci Rep, 2020,10(1): 1866.
KIM J H, YAMAORI S, TANABE T, et al. Implication of intestinal VDR deficiency in inflammatory bowel disease[J]. Biochim Biophys Acta, 2013, 1830(1): 2118-2128.
WADA T, GAO J, XIE W. PXR and CAR in energy metabolism[J].Trends Endocrinol Metab, 2009, 20(6): 273-279.
FRANZOSA E A, SIROTA-MADI A, AVILA-PACHECO J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease[J]. Nat Microbiol, 2019, 4(2): 293-305.
LLOYD-PRICE J, ARZE C, ANANTHAKRISHNAN A N, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases[J]. Nature, 2019, 569(7758): 655-662.
FIORUCCI S, BIAGIOLI M, ZAMPELLA A, et al. Bile acids activated receptors regulate innate immunity[J]. Front Immunol, 2018, 9: 1853.
PERINO A, DEMAGNY H, VELAZQUEZ-VILLEGAS L, et al. Molecular physiology of bile acid signaling in health, disease, and aging[J]. Physiol Rev, 2021, 101(2): 683-731.
KEITEL V, STINDT J, HÄUSSINGER D. Bile acid-activated receptors: GPBAR1 (TGR5) and other G protein-coupled receptors[J]. Handb Exp Pharmacol, 2019, 256: 19-49.
POLS T W, NORIEGA L G, NOMURA M, et al. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation[J]. J Hepatol, 2011, 54(6): 1263-1272.
LAVELLE A, SOKOL H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(4): 223-237.
MACHIELS K, JOOSSENS M, SABINO J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis[J]. Gut, 2014, 63(8): 1275-1283.
YANG Z H, LIU F, ZHU X R, et al. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis[J]. World J Gastroenterol, 2021, 27(24): 3609-3629.
SINHA S R, HAILESELASSIE Y, NGUYEN L P, et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation[J]. Cell Host Microbe, 2020, 27(4): 659-670.
HOFMANN A F. The continuing importance of bile acids in liver and intestinal disease[J]. Arch Intern Med, 1999, 159(22): 2647-2658.
BENNET J D. Ulcerative colitis: the result of an altered bacterial metabolism of bile acids or cholesterol[J]. Med Hypotheses, 1986, 20(2): 125-132.
LIU J, LI Y, SUN C, et al. Geniposide reduces cholesterol accumulation and increases its excretion by regulating the FXR-mediated liver-gut crosstalk of bile acids[J]. Pharmacol Res, 2020, 152: 104631.
YAN X, ZHANG Y, PENG Y, et al. The water extract of Radix scutellariae, its total flavonoids and baicalin inhibited CYP7A1 expression, improved bile acid, and glycolipid metabolism in T2DM mice[J]. J Ethnopharmacol, 2022, 293: 115238.
Explore relationship between gut microbiota and hypertension based on the theory of “the heart and small intestine forming an exterior and interior relationship”
Traditional Chinese medicine treatment for Alzheimer’s disease based on the microbiota⁃brain⁃gut axis
Research progress on mechanisms of traditional Chinese medicine in improving obesity and its related metabolic diseases through gut microbiota
Research progress in anti⁃tumor clinical efficacy and mechanism of action of Sarcandrae Herba
Mechanism of Astragaloside Ⅳ regulates extracellular vesicles⁃mediated JMJD3/H3K27me3/OPN pathway against colorectal cancer liver metastasis
Related Author
No data
Related Institution
Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Shandong University of Traditional Chinese Medicine, Ji’nan
The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji’nan
Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai Key Laboratory of Complex Prescriptions, The MOE Key Laboratory for Standardization of Chinese Medicines and the SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines
Shanghai R & D Center for Standardization of Traditional Chinese Medicines